These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 31695823)

  • 1. Induction of periosteal bone formation by intraosseous BMP-2 injection in a mouse model of osteogenesis imperfecta.
    Cheng TL; Cantrill LC; Schindeler A; Little DG
    J Child Orthop; 2019 Oct; 13(5):543-550. PubMed ID: 31695823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling anabolic and antiresorptive therapies for fracture healing in a mouse model of osteogenesis imperfecta.
    O'Donohue AK; Dao A; Bobyn JD; Munns CF; Little DG; Schindeler A
    J Orthop Res; 2023 Apr; 41(4):808-814. PubMed ID: 35803595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination treatment with growth hormone and zoledronic acid in a mouse model of Osteogenesis imperfecta.
    Lee LR; Holman AE; Li X; Vasiljevski ER; O'Donohue AK; Cheng TL; Little DG; Schindeler A; Biggin A; Munns CF
    Bone; 2022 Jun; 159():116378. PubMed ID: 35257929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone Marrow Transplantation for Treatment of the Col1a2
    Lee LR; Peacock L; Ginn SL; Cantrill LC; Cheng TL; Little DG; Munns CF; Schindeler A
    Calcif Tissue Int; 2019 Apr; 104(4):426-436. PubMed ID: 30535573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination sclerostin antibody and zoledronic acid treatment outperforms either treatment alone in a mouse model of osteogenesis imperfecta.
    Little DG; Peacock L; Mikulec K; Kneissel M; Kramer I; Cheng TL; Schindeler A; Munns C
    Bone; 2017 Aug; 101():96-103. PubMed ID: 28461254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early Fracture Healing is Delayed in the Col1a2
    Besio R; Maruelli S; Battaglia S; Leoni L; Villani S; Layrolle P; Rossi A; Trichet V; Forlino A
    Calcif Tissue Int; 2018 Dec; 103(6):653-662. PubMed ID: 30076439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone mineral properties in growing Col1a2(+/G610C) mice, an animal model of osteogenesis imperfecta.
    Masci M; Wang M; Imbert L; Barnes AM; Spevak L; Lukashova L; Huang Y; Ma Y; Marini JC; Jacobsen CM; Warman ML; Boskey AL
    Bone; 2016 Jun; 87():120-9. PubMed ID: 27083399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adult Brtl/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength.
    Sinder BP; White LE; Salemi JD; Ominsky MS; Caird MS; Marini JC; Kozloff KM
    Osteoporos Int; 2014 Aug; 25(8):2097-107. PubMed ID: 24803333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of treatment with a bone-targeted prostaglandin E2 receptor 4 agonist C3 (Mes-1007) in a mouse model of severe osteogenesis imperfecta.
    Boraschi-Diaz I; Chen G; Polak-Nachumow J; Young RN; Rauch F
    Bone; 2021 Apr; 145():115867. PubMed ID: 33524637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Morphological and mechanical characterization of bone phenotypes in the Amish G610C murine model of osteogenesis imperfecta.
    Kohler R; Tastad CA; Creecy A; Wallace JM
    PLoS One; 2021; 16(8):e0255315. PubMed ID: 34449800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic aptamer targeting sclerostin loop3 for promoting bone formation without increasing cardiovascular risk in osteogenesis imperfecta mice.
    Wang L; Yu Y; Ni S; Li D; Liu J; Xie D; Chu HY; Ren Q; Zhong C; Zhang N; Li N; Sun M; Zhang ZK; Zhuo Z; Zhang H; Zhang S; Li M; Xia W; Zhang Z; Chen L; Shang P; Pan X; Lu A; Zhang BT; Zhang G
    Theranostics; 2022; 12(13):5645-5674. PubMed ID: 35966595
    [No Abstract]   [Full Text] [Related]  

  • 12. Inhibition of TGF-β Increases Bone Volume and Strength in a Mouse Model of Osteogenesis Imperfecta.
    Greene B; Russo RJ; Dwyer S; Malley K; Roberts E; Serrielo J; Piepenhagen P; Cummings S; Ryan S; Zarazinski C; Uppuganti S; Bukanov N; Nyman JS; Cox MK; Liu S; Ibraghimov-Beskrovnaya O; Sabbagh Y
    JBMR Plus; 2021 Sep; 5(9):e10530. PubMed ID: 34532615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are Changes in Composition in Response to Treatment of a Mouse Model of Osteogenesis Imperfecta Sex-dependent?
    Boskey AL; Marino J; Spevak L; Pleshko N; Doty S; Carter EM; Raggio CL
    Clin Orthop Relat Res; 2015 Aug; 473(8):2587-98. PubMed ID: 25903941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone morphogenetic protein-7 selectively enhances mechanically induced bone formation.
    Cheline AJ; Reddi AH; Martin RB
    Bone; 2002 Nov; 31(5):570-4. PubMed ID: 12477570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the LRP5 pathway improves bone properties in a mouse model of osteogenesis imperfecta.
    Jacobsen CM; Barber LA; Ayturk UM; Roberts HJ; Deal LE; Schwartz MA; Weis M; Eyre D; Zurakowski D; Robling AG; Warman ML
    J Bone Miner Res; 2014 Oct; 29(10):2297-306. PubMed ID: 24677211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sclerostin antibody reduces long bone fractures in the oim/oim model of osteogenesis imperfecta.
    Cardinal M; Tys J; Roels T; Lafont S; Ominsky MS; Devogelaer JP; Chappard D; Mabilleau G; Ammann P; Nyssen-Behets C; Manicourt DH
    Bone; 2019 Jul; 124():137-147. PubMed ID: 31051315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapidly growing Brtl/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment.
    Sinder BP; Salemi JD; Ominsky MS; Caird MS; Marini JC; Kozloff KM
    Bone; 2015 Feb; 71():115-23. PubMed ID: 25445450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hindlimb Skeletal Muscle Function and Skeletal Quality and Strength in +/G610C Mice With and Without Weight-Bearing Exercise.
    Jeong Y; Carleton SM; Gentry BA; Yao X; Ferreira JA; Salamango DJ; Weis M; Oestreich AK; Williams AM; McCray MG; Eyre DR; Brown M; Wang Y; Phillips CL
    J Bone Miner Res; 2015 Oct; 30(10):1874-86. PubMed ID: 25829218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced Wnt signaling improves bone mass and strength, but not brittleness, in the Col1a1(+/mov13) mouse model of type I Osteogenesis Imperfecta.
    Jacobsen CM; Schwartz MA; Roberts HJ; Lim KE; Spevak L; Boskey AL; Zurakowski D; Robling AG; Warman ML
    Bone; 2016 Sep; 90():127-32. PubMed ID: 27297606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A xenograft model to evaluate the bone forming effects of sclerostin antibody in human bone derived from pediatric osteogenesis imperfecta patients.
    Surowiec RK; Battle LF; Ward FS; Schlecht SH; Khoury BM; Robbins C; Wojtys EM; Caird MS; Kozloff KM
    Bone; 2020 Jan; 130():115118. PubMed ID: 31678490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.